Literature DB >> 6249133

Coexistent lobular carcinoma in situ and intraductal carcinoma in a single lobular-duct unit.

P P Rosen.   

Abstract

Current classifications of mammary carcinoma generally divide noninvasive disease into two seemingly distinct categories: in situ lobular carcinoma and intraductal carcinoma. The two are considered to be independent entities which may sometimes coexist separately in the same breast. Three cases illustrated in this report each had classical histological changes of noninvasive duct and lobular carcinoma merging in single lobular-duct systems. The morphological separation of lobular carcinoma in situ and intraductal carcinoma may not be clear-cut in all cases. The existence of combined patterns may explain why some patients with untreated in situ lobular carcinoma subsequently develop invasive duct carcinoma.

Entities:  

Mesh:

Year:  1980        PMID: 6249133     DOI: 10.1097/00000478-198006000-00004

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  4 in total

1.  Mixed apocrine/endocrine ductal carcinoma in situ of the breast coexistent with lobular carcinoma in situ.

Authors:  J D Coyne; P A Dervan; L Barr; A D Baildam
Journal:  J Clin Pathol       Date:  2001-01       Impact factor: 3.411

Review 2.  Management of in situ and minimally invasive breast carcinoma.

Authors:  E R Frykberg; K I Bland
Journal:  World J Surg       Date:  1994 Jan-Feb       Impact factor: 3.352

3.  E-cadherin expression: a diagnostic utility for differentiating breast carcinomas with ductal and lobular morphologies.

Authors:  Kanthilatha Pai; Poornima Baliga; Bishwo Lal Shrestha
Journal:  J Clin Diagn Res       Date:  2013-03-18

Review 4.  The diagnosis and management of pre-invasive breast disease: pathology of atypical lobular hyperplasia and lobular carcinoma in situ.

Authors:  Peter T Simpson; Theodora Gale; Laura G Fulford; Jorge S Reis-Filho; Sunil R Lakhani
Journal:  Breast Cancer Res       Date:  2003-07-29       Impact factor: 6.466

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.